MedX Health with ProMed Pharmacy and Dura Wellness Clinic launches Dermsecure® Screening

MISSISSAUGA, Ontario–(BUSINESS WIRE)–$MDX #SkinCancer–Teledermatology company MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce the launch of MedX Screening Services to be offered at two locations in Ottawa, Canada – ProMed Pharmacy, an independent, pharmacist owned pharmacy enterprise, and Dura Wellness Clinic a retail, clinical focused esthetic services group. Both locations will now offer MedX scanning services and accept walk-in patients.

“This represents the next step in our business plan for North America,” stated MedX VP of North American Sales, Paul Ziemer. “ProMed Pharmacy, under the Leadership of Lubna Fawaz, is a perfect model of modern health care delivery as it integrates many services and, most importantly, telehealth services on demand for their patients. Patients can now enter the pharmacy and have a telemedicine consult with a General Practitioner and receive an immediate referral to the Dermsecure Screening Service on site. Incorporating a telemedicine consult with a General Practitioner is a vital step to make DermSecure screening services easily accessible to the public by facilitating both the referral and the screening at the same location.”

ProMed Pharmacy now offering MedX Health Dermatological Screening Services:

  • 2706 Alta Vista Dr. Ottawa, Ontario (Tel: 613-680-4343)

    • 2 Pharmacists on staff
    • Pharmacist Owner – Lubna Fawaz

Dura Wellness Clinic is now offering MedX Health Dermatological Screening Services:

  • 2283 St. Laurent Blvd, Suite 106, Ottawa, Ontario (Tel: 613-518-5886)

    • 2 Pedorthists on Staff
    • High Volume Clinical Practice with focus on Biomechanics and Patient Gait
    • Retail location offering Telemedicine, Orthotics, Compression wear and Body Bracing products

MedX continues to focus on expanding its DermSecure® Screening Platform network across North America. To date, its business model has been focused on adding multiple market verticals, such as Medical Clinic and Building Hubs, Medical Scanning Clinics, Mobile and Remote Medical Practices, Esthetics and Skin Care Clinics.

The addition of ProMed Pharmacy to MedX’s Pharmacy network will allow for the “Walk-in-Patient” to get service for their Dermatology concerns if they do not have a Family Doctor or do not have time to get a direct referral.

“MedX remains focused on expanding its footprint into existing and new target markets, and our team is continuing to establish and accelerate many new commercial relationships and partnerships,” stated Mike Druhan, MedX President, Dermatology Services. “I remain confident in our team’s ability to expand MedX’s teledermatology platform to new markets and greatly improve outcomes for those dermatology patients seeking high-quality, virtual services.”

Teledermatology is a subspecialty of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. MedX is a global leader in teledermatology through its high-definition image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology globally that captures five high-resolution images of suspicious moles, lesions and skin conditions, including four spectrophotometric images 2mm below the skin’s surface. This technology provides detailed patient scans for virtual dermatological assessment by a certified dermatologist within 72 hours.

About MedX Health Corp.:

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.


Bill Mitoulas, Investor Relations

MedX Health Corp.